Journal ArticleDOI
Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
Reads0
Chats0
TLDR
GPC3 is a potential and reliable biomarker for predicting tumor recurrence and overall survival in HCC patients after curative resection and could predict the outcomes of patients with stage I disease.About:
This article is published in Surgery.The article was published on 2013-09-01. It has received 70 citations till now. The article focuses on the topics: Survival analysis & Hazard ratio.read more
Citations
More filters
Journal ArticleDOI
Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment
TL;DR: The current knowledge regarding the structure, function, and biology of GPC3 is summarized with a focus on its clinical potential as a diagnostic molecule and a therapeutic target in HCC immunotherapy.
Journal ArticleDOI
Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma
Min Yu,Hong Luo,Mingliang Fan,Xiuqi Wu,Bizhi Shi,Shengmeng Di,Ying Liu,Zeyan Pan,Hua Jiang,Zonghai Li +9 more
TL;DR: Clinical translation of this GPC3-specific, NK cell-based therapeutic as a novel treatment option for patients with G PC3+ HCC is justified.
Journal ArticleDOI
Competing risk bias was common in Kaplan-Meier risk estimates published in prominent medical journals.
TL;DR: Almost half of Kaplan-Meier analyses published in medical journals are susceptible to competing risk bias and may overestimate event risk and this bias was found to be quantitatively important in a third of such studies.
Journal ArticleDOI
Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma
TL;DR: Current knowledge regarding the clinical implication of GPC3 detection and targeting in the management of patients with HCC is summarized.
Journal ArticleDOI
Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials
Bruna Scaggiante,Maryam Kazemi,Gabriele Pozzato,Barbara Dapas,Rossella Farra,Mario Grassi,Fabrizio Zanconati,Gabriele Grassi +7 more
TL;DR: It is believed that integrated researches among the different lines of investigation indicated above should represent the winning strategies to identify effective HCC markers and therapeutic targets.
References
More filters
Journal ArticleDOI
Management of hepatocellular carcinoma: An update
Jordi Bruix,Morris Sherman +1 more
TL;DR: The American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) were updated in 2010 as discussed by the authors.
AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma: An Update
Jordi Bruix,Morris Sherman +1 more
TL;DR: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
Journal ArticleDOI
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
TL;DR: A detailed understanding of epidemiologic factors and molecular mechanisms associated with HCC ultimately could improve current concepts for screening and treatment of this disease.
Journal ArticleDOI
Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.
Journal ArticleDOI
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
Mariana Capurro,Ian R. Wanless,Morris Sherman,Gerrit DeBoer,Wen Shi,Eiji Miyoshi,Jorge Filmus +6 more
TL;DR: GPC3 is specifically overexpressed in most HCCs and is elevated in the serum of a large proportion of patients with HCC, suggesting that the simultaneous determination of GPC3 and AFP may significantly increase the sensitivity for diagnosis of HCC.